Useful therapies are available for virtually every patient with multiple sclerosis. FDA-approved medications currently in use have had major beneficial impact on disease activity in many patients, but we must do better. We must develop therapies with even more potency in disease control, less potential of toxicity, and improved ease of administration and patient comfort.
Questions? Please call:
Kay Hartley, R.N.
Clinical Coordinator
Providence Multiple Sclerosis Center
Phone: 503-216-1064 Fax: 503-216-1066
Current clinical trials underway at Providence Multiple Sclerosis Center
Actively recruiting patients:
Sanofi Aventis protocol number EFC10531
TOWER: A multicenter, double-blind, parallel-group, placebo-controlled study of the efficacy and safety of teriflunomide in patients with relapsing multiple sclerosis using interferon-beta 1a (Rebif®) as an open-label rater-blind calibrator
This study is for patients with relapsing multiple sclerosis. Patients are randomly assigned (by chance) to one of two different doses of an investigational medication (not approved by the FDA) called Teriflunomide that is taken by mouth, or placebo (inactive look-alike capsule). Patients must not have had taken Copaxone, Avonex, Rebif or Betaseron in the previous three months, and cannot have taken Tysabri at any time.
Sponsor: Sonofi-Aventis Research and Development Principal Investigator: Stanley Cohan, M.D., Ph.D.
If you are interested in this study in particular, please contact Chad Parks, Clinical Research Coordinator, at 503-216-2736.
Sanofi Aventis protocol number DRI10566
NEWS: A 14-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy, Safety and Tolerability of Nerispirdine 50 mg, 100 mg, and 200 mg in Patients with Multiple Sclerosis.
This study is for patients diagnosed with any type of MS who are experiencing walking disability. Patients are randomly assigned (by chance) to one of 3 different doses of an investigational medication (not approved by the FDA) called nerispirdine that is taken by mouth, or placebo (inactive look-alike tablet). Patients must not have had a relapse in the past six months. Participation will last approximately 19 weeks total.
Sponsor:Sanofi-Aventis Research and Development Principal Investigator: Stanley Cohan, M.D., Ph.D.
If you are interested in this study in particular, please contact Chad Parks, Clinical Research Coordinator, at 503-216-2736.
Biogen Idec protocol number 10-MS-402:
TYGRIS: Tysabri global observational program in safety
Closed to recruitment:
Teva Pharmaceutical Industries protocol number MS-LAQ-302
BRAVO: A multinational, multicenter, randomized, parallel-group study performed in subjects with relapsing-remitting multiple sclerosis to assess the efficacy, safety and tolerability of Laquinimod over placebo in a double-blind design and of a reference arm of Interferon beta-1a (Avonex) in a rater-blinded design
Biogen Idec protocol number 001-06-NAT
The ENER-G Study: A multicenter, open-label study to evaluate the effects of natalizumab treatment on fatigue and cognition in subjects with relapsing forms of MS
Biogen Idec protocol number 109MS302
CONFIRM: A randomized, multicenter, placebo-controlled and active reference (glatiramer acetate) comparison study to evaluate the efficacy and safety of BG00012 in subjects with relapsing-remitting multiple sclerosis
